All In MedTech

Device Trial Radar · NCT06389071

Laser Treatment for Lichen Sclerosus

Safety and Efficacy of Ablative Fractional 2940 nm Laser Treatment for Lichen Sclerosus Lesion

Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Mar 1, 2024

Primary completion

Jul 20, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
ScitonNot on our public-company list
Sponsor type
Industry
First posted
Apr 29, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Fractional ablative laser treatment for Lichen Sclerosus lesion

Conditions

  • Lichen Sclerosus Lesion

Interventions

  • Fractional 2940 nm LaserDevice

    Fractional 2940 nm Laser

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Histological clearanceTime frame: 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinique Medicale Uro-Gyneco de l'Abitibi

    Val-d'Or, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.